IMEMR
EMRO
66.92
Index Copernicus
ICICICICICICICIC
Volume 1, Issue 3 (2020)
J Clinic Care Skill 2020, 1(3): 127-132 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Abassi R, Abassi F, Mosavizadeh A, Sadeghi H, Keshtkari A. Comparison the Effect of Omeprazole, Esomeprazole and Lansoprazole on Treatment of Gastroesophageal Reflux Disease in Infants. J Clinic Care Skill 2020; 1 (3) :127-132
URL: http://jccs.yums.ac.ir/article-1-49-en.html
URL: http://jccs.yums.ac.ir/article-1-49-en.html
1- Pediatrics Department, Medicine Faculty, Yasuj University of Medical Sciences, Yasuj, Iran
2- Social Determinants of Health Research Center, Yasuj University of Medical Sciences, Yasuj, Iran
3- Medicinal Plants Research Center, Yasuj University of Medical Sciences, Yasuj, Iran
4- Pediatrics Department, Medicine Faculty, Yasuj University of Medical Sciences, Yasuj, Iran , a_keshtkari@yahoo.com
2- Social Determinants of Health Research Center, Yasuj University of Medical Sciences, Yasuj, Iran
3- Medicinal Plants Research Center, Yasuj University of Medical Sciences, Yasuj, Iran
4- Pediatrics Department, Medicine Faculty, Yasuj University of Medical Sciences, Yasuj, Iran , a_keshtkari@yahoo.com
Abstract: (4703 Views)
Aims: Gastroesophageal reflux Disease (GERD) results impairment in the quality of life of the infants. Various studies have shown that proton pump inhibitors have a beneficial effect on the treatment of GERD. The aim of this study was to compare the effect of omeprazole, esomeprazole, and lansoprazole in the treatment of GERD in infants.
Materials & Method: This study is a randomized double blinded clinical trial that was conducted on 2-24-month-old infants with GERD referred to the Shahid Mofatteh clinic in Yasuj, Iran in 2016. 90 samples were selected by purposive sampling method and randomly assigned to three intervention groups including lansoprazole, omeprazole and esomeprazole (30 subjects per group). Infants in each group daily received 1mg/kg body weight of their prescription drugs. Before and after two and four weeks of treatment, the GERD-Q questionnaire was completed. Data were analyzed by SPSS 21 software using statistical tests.
Findings: There was no significant difference in the severity of GERD among the 3 groups before and 2 and 4 weeks after the intervention. Although, esomeprazole had a greater and faster effect on recovery. The symptoms of GERD in esomeprazole group were similar to the other two groups, but this difference was not significant. However, each of the three interventions alone improved GERD.
Conclusion: All three drugs, lansoprazole, omeprazole, and esomeprazole, are effective on GERD recovery. In comparison, although there is no significant difference among these 3 drugs, However esomeprazole appears to have a better clinical effect.
Materials & Method: This study is a randomized double blinded clinical trial that was conducted on 2-24-month-old infants with GERD referred to the Shahid Mofatteh clinic in Yasuj, Iran in 2016. 90 samples were selected by purposive sampling method and randomly assigned to three intervention groups including lansoprazole, omeprazole and esomeprazole (30 subjects per group). Infants in each group daily received 1mg/kg body weight of their prescription drugs. Before and after two and four weeks of treatment, the GERD-Q questionnaire was completed. Data were analyzed by SPSS 21 software using statistical tests.
Findings: There was no significant difference in the severity of GERD among the 3 groups before and 2 and 4 weeks after the intervention. Although, esomeprazole had a greater and faster effect on recovery. The symptoms of GERD in esomeprazole group were similar to the other two groups, but this difference was not significant. However, each of the three interventions alone improved GERD.
Conclusion: All three drugs, lansoprazole, omeprazole, and esomeprazole, are effective on GERD recovery. In comparison, although there is no significant difference among these 3 drugs, However esomeprazole appears to have a better clinical effect.
Article Type: Original Research |
Subject:
Special
Received: 2019/01/22 | Accepted: 2019/07/4 | Published: 2020/09/21
Received: 2019/01/22 | Accepted: 2019/07/4 | Published: 2020/09/21
References
1. Jung HK. Epidemiology of gastroesophageal reflux disease in Asia: a systematic review. J Neurogastroenterol Motil. 2011;17(1):14-27. [Link] [DOI:10.5056/jnm.2011.17.1.14]
2. Bahremand S, Jalili N, Mohammadnejad E, Zebardast J, Khatibi A. Assessment clinical features of gastro esophageal reflux diseases in infants. Zahedan J Res Med Sci. 2012;13(Suppl 1):3. [Persian] [Link]
3. Hatami K, Pourshams A, Azimi K, Sarrafi M, Mehrabani M, Mostajabi P, et al. Dyspepsia, gastroesophageal reflux disease and irritable bowel syndrome among blood donors. Govaresh. 2003;8(4):138-46. [Persian] [Link]
4. Kothari S, Nelson SP, Wu EQ, Beaulieu N, McHale JM, Dabbous OH. Healthcare costs of GERD and acid-related conditions in pediatric patients, with comparison between histamine-2 receptor antagonists and proton pump inhibitors. Curr Med Res Opin. 2009;25(11):2703-9. [Link] [DOI:10.1185/03007990903307755]
5. Pourshams A, Rahmani AR, Hatami K. Gastroesophageal reflux disease in Iran. Govaresh. 2005;10(1):48-53. [Link]
6. Fujiwara Y, Machida A, Watanabe Y, Shiba M, Tominaga K, Watanabe T, et al. Association between dinner- to-bed time and gastro-esophageal reflux disease. Am J Gastroenterol. 2005;100(12):2633-6. [Link] [DOI:10.1111/j.1572-0241.2005.00354.x]
7. Kahrilas PJ, Shaheen NJ, Vaezi MF, Hiltz SW, Black E, Modlin IM, et al. American gastroenterological association medical position statement on the management of gastroesophageal reflux disease. Gastroenterology. 2008;135(4):1383-91.
https://doi.org/10.1053/j.gastro.2008.08.044 [Link] [DOI:10.1053/j.gastro.2008.08.045]
8. Koda YK, Ozaki MJ, Murasca K, Vidolin E. Clinical features and prevalence of gastroesophageal reflux disease in infants attending a pediatric gastroenterology reference service. Arq Gastroenterol. 2010;47(1):66-71. [Link] [DOI:10.1590/S0004-28032010000100012]
9. Hegar B, Vandenplas Y. Gastroesophageal reflux: natural evolution, diagnostic approach and treatment. Turkish J Pediatr. 2013;55:1-7. [Link]
10. Kleinman L, Rothman M, Strauss R, Orenstein SR, Nelson S, Vandenplas Y, et al. The infant gastroesophageal reflux questionnaire revised: development and validation as an evaluative instrument. Clin Gastroenterol Hepatol. 2006;4(5):588-96. [Link] [DOI:10.1016/j.cgh.2006.02.016]
11. Yoshikawa, Hiroo, et al. Oral symptoms including dental erosion in gastroesophageal reflux disease are associated with decreased salivary flow volume and swallowing function. J Gastroenterol. 2012;47(4):412-20. [Link] [DOI:10.1007/s00535-011-0515-6]
12. Vandenplas Y, Rudolph CD, Di Lorenzo C, Hassall E, Liptak G, Mazur L, et al. Pediatric gastroesophageal reflux clinical practice guidelines: joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN). J Pediatr Gastroenterol Nutr. 2009;49(4):498-547. [Link] [DOI:10.1097/MPG.0b013e3181b7f563]
13. Wiersma HE, van Boxtel CJ, Butter JJ, van Aalderen WM, Omari T, Benninga MA. Pharmacokinetics of a single oral dose of baclofen in pediatric patients with gastroesophageal reflux disease. Ther Drug Monit. 2003;25(1):93-8. [Link] [DOI:10.1097/00007691-200302000-00014]
14. Higginbotham TW. Effectiveness and safety of proton pump inhibitors in infantile gastroesophageal reflux disease. Ann Pharmacother. 2010;44(3):572-6. [Link] [DOI:10.1345/aph.1M519]
15. Badiola N, Alcalde V, Pujol A, Münter LM, Multhaup G, Lleó A, et al. The proton-pump inhibitor lansoprazole enhances amyloid beta production. PloS One. 2013;8(3):e58837. [Link] [DOI:10.1371/journal.pone.0058837]
16. Sahara S, Sugimoto M, Uotani T, Ichikawa H, Yamade M, Iwaizumi M, et al. Twice‐daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice‐daily omeprazole, rabeprazole or lansoprazole. Aliment Pharmacol Ther. 2013;38(9):1129-37. [Link] [DOI:10.1111/apt.12492]
17. Chen IL, Gao WY, Johnson AP, Niak A, Troiani J, Korvick J, et al. Proton pump inhibitor use in infants: FDA reviewer experience. J Pediatr Gastroenterol Nutr. 2012;54(1):8-14. [Link] [DOI:10.1097/MPG.0b013e31823890b4]
18. Orenstein SR, Hassall E, Furmaga-Jablonska W, Atkinson S, Raanan M. Multicenter, double-blind, randomized, placebo-controlled trial assessing the efficacy and safety of proton pump inhibitor lansoprazole in infants with symptoms of gastroesophageal reflux disease. J Pediatr. 2009;154(4):514-20.e4. [Link] [DOI:10.1016/j.jpeds.2008.09.054]
19. Winter H, Gunasekaran T, Tolia V, Gottrand F, Barker PN, Illueca M. Esomeprazole for the treatment of GERD in infants ages 1-11 months. J Pediatr Gastroenterol Nutr. 2012;55(1):14-20. [Link]
20. Tolia V, Gilger MA, Barker PN, Illueca M. Healing of erosive esophagitis and improvement of symptoms of gastroesophageal reflux disease after esomeprazole treatment in children 12 to 36 months old. J Pediatr Gastroenterol Nutr. 2015; 60 Suppl 1:S31-6. [Link] [DOI:10.1097/MPG.0b013e3181ddcf11]
21. Omari TI, Haslam RR, Lundborg P, Davidson GP. Effect of omeprazole on acid gastroesophageal reflux and gastric acidity in preterm infants with pathological acid reflux. J Pediatr Gastroenterol Nutr. 2007;44(1):41-4. [Link] [DOI:10.1097/01.mpg.0000252190.97545.07]
22. Khoshoo V, Dhume P. Clinical response to 2 dosing regimens of lansoprazole in infants with gastroesophageal reflux. J Pediatr Gastroenterol Nutr. 2008;46(3):352-4. [Link] [DOI:10.1097/MPG.0b013e31815667d7]
23. Tighe MP, Afzal NA, Bevan A, Beattie RM. Current pharmacological management of gastro-esophageal reflux in children: an evidence-based systematic review. Pediatr Drugs. 2009;11(3):185-202. [Link] [DOI:10.2165/00148581-200911030-00004]
24. Nasseri-Moghaddam S, Tofangchiha S, Azimi K, Ostad Rahimi S, Malekzadeh R. Comparing different brands of Omeprazole with Pantozole in GERD patients. J Army Univ Med Sci. 2010;8(2):132-7. [Persian] [Link]
25. Richter JE, Kahrilas PJ, Johanson J, Maton P, Breiter JR, Hwang C, et al. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. Am J Gastroenterol. 2001;96(3):656-65. [Link] [DOI:10.1111/j.1572-0241.2001.03600.x]
26. Zheng RN. Comparative study of omeprazole, lansoprazole, pantoprazole and esomeprazole for symptom relief in patients with reflux esophagitis. World J Gastroenterol. 2009;15(8):990-5. [Link] [DOI:10.3748/wjg.15.990]
27. Röhss K, Wilder-Smith C, Nauclér E, Jansson L. Esomeprazole 20mg provides more effective intragastric acid control than maintenance-dose rabeprazole, lansoprazole or pantoprazole in healthy volunteers. Clin Drug Investig. 2004;24(1):1-7. [Link] [DOI:10.2165/00044011-200424010-00001]
28. Tjon JA, Pe M, Soscia J, Mahant S. Efficacy and safety of proton pump inhibitors in the management of pediatric gastroesophageal reflux disease. Pharmacotherapy. 2013;33(9):956-71. [Link] [DOI:10.1002/phar.1299]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |